Hepion Pharmaceuticals replaces auditor Grassi with Rosenberg Rich Baker Berman
Bitget2026/09/28 10:31- Hepion Pharmaceuticals dismissed auditor Grassi & Co. effective Sept. 22, 2026.
- Rosenberg Rich Baker Berman hired to audit 2026 consolidated financial statements.
- Prior audit reports included a going-concern warning tied to significant operating losses and negative operating cash flow since inception.
- Company reported no accounting or audit-scope disputes with Grassi for 2024-2025 or through Sept. 21, 2026.
- Material weaknesses in internal control over financial reporting were disclosed in recent filings, cited as the only reportable events.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
